Form 4: Medpace Director Receives Stock Option Grant

Medpace Holdings, Inc. director Cornelius P. McCarthy III was granted 1,110 stock options as part of standard equity compensation.

Summary

• Director Cornelius P. McCarthy III received a grant of 1,110 stock options for Medpace Holdings, Inc. (MEDP) common stock.
• The options have an exercise price of $415.27 per share.
• The grant date for these options is May 15, 2026.
• The options are scheduled to vest on the earlier of the day before the next annual meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market price volatility could impact the value of the options relative to the exercise price.

Future Outlook

The options vest on the earlier of the day preceding the next annual meeting or the first anniversary of the grant, contingent on continued board service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the clinical research organization (CRO) sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant structure follows standard industry practices for equity-based director compensation.
• Vesting schedules are consistent with typical annual equity refresh cycles for public company boards.

Stakeholder Impact

• Minor dilution impact for shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on or before May 15, 2027.

Key Dates

Keywords

Medpace, MEDP, Form 4, Insider Trading, Stock Options, Director Compensation